Denise K Nawrocki

Development of stable liquid formulations for adenovirus-based vaccines.

R. K. Evans, J. Shiver, D. Volkin, 2004, Journal of pharmaceutical sciences.

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

R. K. Evans, T. Toner, J. Shiver, 2003, Journal of Virology.

Vaccine-Induced Immunity in Baboons by Using DNA and Replication-Incompetent Adenovirus Type 5 Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

R. K. Evans, J. Shiver, E. Emini, 2003, Journal of Virology.

Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain.

J. Heinrichs, C. Gaunt, Lani Indrawati, 2017, Vaccine.

Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models.

J. Joyce, Julie M. Skinner, S. Curry, 2022, Vaccine.

Enabling Lyophilized Pneumococcal Conjugate Vaccines Through Formulation Design and Excipient Selection Suitable for A Multivalent Adjuvanted Vaccine.

A. Bhambhani, J. Blue, Ramesh Chintala, 2020, Journal of pharmaceutical sciences.

Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines.

R. K. Evans, J. Shiver, D. Volkin, 2004, Journal of pharmaceutical sciences.